







# Implementation outcomes of tuberculosis digital adherence technologies: a scoping review using the RE-AIM framework

Chimweta I Chilala <sup>1</sup>, Nicola Foster <sup>1</sup>, Shruti Bahukudumbi,<sup>2</sup> Mona Salaheldin Mohamed,<sup>3</sup> Miranda Zary,<sup>3</sup> Cedric Kafie,<sup>3</sup> Barbie Patel,<sup>2</sup> Genevieve Gore <sup>4</sup>, Kevin Schwartzman <sup>3</sup>, Ramnath Subbaraman <sup>2,5</sup>, Katherine L Fielding <sup>1</sup>

**To cite:** Chilala CI, Foster N, Bahukudumbi S, *et al.* Implementation outcomes of tuberculosis digital adherence technologies: a scoping review using the RE-AIM framework. *BMJ Glob Health* 2025;**10**:e016535. doi:10.1136/bmjgh-2024-016535

**Handling editor** Alberto L Garcia-Basteiro

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/bmjgh-2024-016535>).

Received 10 September 2024  
Accepted 28 December 2024



► <http://dx.doi.org/10.1136/bmjgh-2024-016608>



© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.

For numbered affiliations see end of article.

## Correspondence to

Professor Katherine L Fielding;  
[katherine.fielding@lshtm.ac.uk](mailto:katherine.fielding@lshtm.ac.uk)

## ABSTRACT

**Introduction** Globally, tuberculosis (TB) remains one of the leading infectious causes of death, with 1.3 million deaths. Digital adherence technologies (DATs) have the potential to provide person-centred care and improve outcomes. Using the reach, effectiveness, adoption, implementation and maintenance (RE-AIM) framework, we conducted a scoping review of DAT implementations for TB treatment.

**Methods** We searched seven databases for papers published between January 2000 and April 2023, using keywords for 'tuberculosis' and 'digital adherence technology'. Articles meeting prespecified inclusion criteria and containing data on RE-AIM domains were included. We defined 'reach' as comprising cellphone ownership and engagement by people with TB (PWTB) with DATs, 'adoption' as engagement by healthcare providers with DAT programmes, 'implementation' as the fidelity of the DAT programme implemented and 'maintenance' as longer-term uptake of DATs.

**Results** Of 10 313 records, 102 contributed to the synthesis. DATs included short message service (SMS), phone, 99DOTS, video-supported therapy (VST) and pillboxes. For 'reach', across various settings, cellphone access varied from 50%–100% and 2%–31% of PWTB was excluded from accessing DATs due to technology challenges. 36%–100% of PWTB agreed to use a DAT. The weighted mean of DAT engagement over dose-days was 81% for SMS, 85% for phone, 61% for 99DOTS, 87% for pillbox and 82% for VST. Concerning 'implementation', the fidelity of DAT implementations was affected by technological issues such as cellphone coverage, DAT malfunction and provider-facing issues, including failure to initiate intensified patient management following low DAT engagement. Findings related to RE-AIM dimensions of 'adoption' and 'maintenance' were limited.

**Conclusion** Our findings suggest that the 'reach' of DATs may be limited by a cascade of barriers, including limitations in cellphone accessibility and suboptimal sustained DAT engagement by PWTB. Video and pillbox DATs have higher levels of engagement. Implementation

## WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ There is significant interest in understanding whether digital adherence technologies (DATs) can improve treatment outcomes for people with tuberculosis (TB). Evaluations across different settings and DAT types (such as short message service, digital pillbox and video-supported therapy) showed varied results in terms of effectiveness and limited generalisability. Extending our understanding of DAT interventions beyond the usual health outcome-based reviews will provide important insights into these results.

## WHAT THIS STUDY ADDS

⇒ Using the RE-AIM framework, this is the first scoping review to systematically synthesise implementation outcomes from DAT evaluations for TB. Our findings suggest that the 'reach' of DATs may be limited by a cascade of barriers, including limitations in cellphone accessibility and suboptimal sustained DAT engagement by people with TB. Video and pillbox DATs have higher levels of engagement. Implementation challenges included technological and provider-facing issues. Findings related to reach, effectiveness, adoption, implementation and maintenance dimensions of 'adoption' and 'maintenance' were limited.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The issues identified through our scoping review can inform how DAT interventions could be adapted to increase equitable access to such technologies and improve treatment outcomes.

challenges included technological and provider-facing issues. Improving implementation outcomes may be important for TB DATs to achieve a broader public health impact.

**PROSPERO registration number** CRD42022326968

## INTRODUCTION

Despite a remarkable global recovery in tuberculosis (TB) notifications reporting, diagnosis and treatment following the disruptive impact of the COVID-19 pandemic, TB remains the leading cause of death from a single infectious agent accounting for nearly 1.25 million deaths annually.<sup>1</sup> Completion of TB treatment and treatment adherence are crucial to the success of TB care programmes broadly. In 2022, treatment success rates were 85% worldwide, though success rates vary substantially by country and for different subpopulations of people with TB (PWTB).<sup>1</sup> For the last few decades, directly observed therapy (DOT) was promoted as a strategy for monitoring adherence to medications by PWTB to address the persistence of the TB global pandemic.<sup>2</sup> DOT requires patient self-management, frequent and timely monitoring, and surveillance at the health facility which places a substantial burden on PWTB and providers.

Digital adherence technologies (DATs), such as short message service (SMS) reminders, feature (non-smart) phones, video-supported therapy (VST), smart digital pillboxes and ingestion sensors, have the potential to address these concerns.<sup>3 4</sup> Understanding their effects on TB care has resulted in a large number of evaluations, particularly over the last 10 years, though evidence for effectiveness on treatment adherence and outcomes showed varied results and with limited generalisability.<sup>5 6</sup> VST evaluations, predominantly conducted in upper-middle and upper-income settings, suggest the DAT is promising, as do approaches that combine DATs with other non-digital approaches.<sup>6</sup> DATs evaluated in low-income and lower-middle-income settings which focused on pillboxes, SMS reminders and medication sleeves with phone calls (branded as '99DOTS'), show no tangible benefits on treatment outcomes.<sup>6</sup> Implementation of DATs in a range of settings, including the coverage of such technologies and fidelity to the planned interventions from the provider's perspective, is important for understanding the successes and challenges in delivering these new approaches for TB care, and particularly important given the mixed effectiveness results. Evidence synthesis for DAT implementation has not been conducted to date. The RE-AIM framework, based on five dimensions, reach, effectiveness, adoption, implementation and maintenance, is used to characterise the public health impact of an intervention.<sup>7</sup>

Using the RE-AIM framework, we conducted a scoping review and meta-analysis of the implementation of DATs for TB and *Mycobacterium tuberculosis* infection treatment in high-income and low-income and middle-income countries. The focus of our scoping review was on the quantitative indicators used within this framework, assessing reported implementation outcomes. A companion review covers contextual factors that influence DAT implementation.<sup>8</sup>

## METHODS

### Population, Intervention, Comparison, Outcomes and Study framework and scoping review design

We followed a rigorous systematic methodology, having originally designed this study as a systematic review, then later modified it to a scoping review due to high heterogeneity in the studies and measures of interest. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews (PRISMA) guidelines (online supplemental appendix 1).<sup>9</sup> Our published review protocol is available from PROSPERO (CRD4022326968). Assessment of the risk of bias for the included studies has not been conducted. We used the Population, Intervention, Comparison, Outcomes and Study framework to define our study population, intervention of interest, comparator and study design (online supplemental appendix 2 and table S1) and used the RE-AIM framework to identify and analyse the implementation-related outcomes from studies using DATs. The RE-AIM framework was chosen as it not only focuses on reach (and effectiveness) but also has dimensions on adoption, implementation and maintenance. We judged the latter three to be important in assessing implementation of the interventions, particularly given the experience of the TB community with such interventions. The study populations included PWTB, people with *M. tuberculosis* infection and other individuals such as healthcare workers, programmes managers or policy-makers (subsequently referred to as healthcare providers (HCP)) who are involved in the implementation of DATs within health systems for TB care. Interventions of interest were DATs which can aid the monitoring and support of TB medication adherence. These technologies included SMS, feature phone and smartphone technologies, digital pillboxes, VST, web-based approaches and ingestion sensors. Included studies may or may not have had a comparator group. We included observational and randomised studies in this review (online supplemental table S1).

### Search strategy

We systematically searched Medline/Ovid, Embase, Cochrane Central Register of Controlled Trials, CINAHL, Web of Science, ClinicalTrials.gov and Europe PMC, using keywords for "tuberculosis" (including both active TB disease and *M. tuberculosis* infection) and "digital adherence technology" (online supplemental table S2). A Health Librarian conducted the search. Our initial search was from 1 January 2000 to 1 April 2022 and was then updated to cover the period from 2 April 2022 to 25 April 2023. We did not restrict to English-language journals.

### Study screening and data extraction

The search results were imported into EndNote where duplicates were removed and underwent two-level blinded screening by two authors (CIC, SB, MSM, CK, MZ and NF) independently in Rayyan (Rayyan, Cambridge

USA). Conflicts were resolved by the senior investigators (KLF, RS and KS). The first level of screening involved title and abstract screening and the second level was full-text screening against prespecified inclusion/exclusion criteria (online supplemental table S3). We were inclusive in the second screen, with reasons for exclusion being (1) not satisfying our case definition for TB and/or DATs; (2) wrong publication type; (3) no primary data related to quantitative implementation outcomes or (4) duplicates. Reasons for exclusion were noted and summarised in the PRISMA flow chart (online supplemental figure S1).

For articles fulfilling criteria for the first and second-level screens, quantitative outcome data on the dimensions of the RE-AIM framework were extracted from the full text using a standard extraction form. One reviewer extracted the data which was verified by a second reviewer, and any conflicts were resolved by discussion between the reviewers, with input from a third reviewer when necessary. The extracted data included the following: study characteristics (name of the author, publication year, country, study design, study setting and the aim of the study); participant characteristics (TB disease, *M. tuberculosis* infection, drug resistance, HIV status); DAT intervention (type of DAT, duration) and quantitative outcomes data using the RE-AIM framework, as described below. Some articles initially eligible for data extraction were subsequently excluded, following attempted data extraction, as no RE-AIM quantitative outcomes data were reported. To confirm the validity of our search and identify any outstanding references, we extracted references from all systematic reviews identified from our initial search (see exclusion criteria), and these references were screened for eligibility. For one article, initially included as a preprint, we abstracted data from the supplement of the subsequently published article.<sup>10</sup>

### RE-AIM framework

The domains of the RE-AIM framework are 'reach', 'effectiveness', 'adoption', 'implementation' and 'maintenance'. We defined reach, among people taking treatment for TB disease or infection, as measures of engagement with a DAT and deconstructed these into three categories: A—the proportion of people with the potential to use or receive DATs (including requirements for cellphone access); B—the proportion of people with any uptake of or engagement with DATs and C—the quality and/or duration of engagement with DATs. Adoption refers to measures of DAT engagement by HCPs. Implementation was measured through the fidelity of the intervention, that is, the extent to which the DAT intervention is operated as intended. Implementation outcomes were grouped into technology-related (the extent to which the DAT functioned as intended) and provider fidelity-related (the extent to which HCPs delivering the intervention adhered to the planned/designed intervention). Finally, the extent to which DATs become integrated into routine care was captured under maintenance (online

supplemental table S4). The effectiveness domain was covered in a related review.<sup>6</sup>

Though not originally planned, we also extracted as part of reach category A data on cellphone sharing, defined as shared versus own phone not shared, by people on treatment for TB disease or infection or potentially eligible for TB preventive therapy (eg, household contacts of a person diagnosed with TB).

### Analysis

DAT interventions which included more than one component, for example, digital pillboxes with SMS reminders, were analysed based on the DAT considered as primary to the intervention. Binary outcomes, reflecting a consistent measure of reach indicators A and B, were summarised as the number of individuals satisfying the indicator divided by the relevant denominator, alongside a 95% Confidence interval (CI) and displayed using forest plots. Where relevant, plots were stratified by income level of the country where the study was conducted, grouped as low-income or low-middle-income (L/LMIC), upper-middle-income (UMIC) or high-income (HIC); DAT type or TB type. CIs for proportions were exact Clopper-Pearson intervals, with a continuity correction of 0.5 applied for measures with zero cells.

For reach C, two main measures were extracted to capture DAT engagement over the entire treatment period: a binary measure of the proportion of individuals with DAT engagement greater than a given threshold as reported by the original studies (ie, a cut-off point; eg, >80%, >90%) and a measure of dose-days with DAT-engagement. When binary measures were reported as less than a cut-off, the data were converted to a positive measure. A pooled estimate, by engagement level, across studies was calculated using random effects meta-analysis, across all DAT types and  $I^2$  statistic summarising heterogeneity reported. In subgroup analyses by DAT types, we opted not to produce summary measures due to the small number of estimates per DAT type and cut-off point. Publication bias was assessed using Doi plots in keeping with guidance for meta-analyses of proportions, using the Luis Furuya-Kanamori (LFK) index.<sup>11–13</sup> This was conducted for all studies with DAT engagement threshold of >90%. The second measure of dose-days with DAT-engagement was extracted from reports either as an average, often the arithmetic mean, of the measure across individuals or as an overall proportion (DAT-engagement days/all dose-days), ignoring individuals; for both measures, a standard error accounting for clustering was often not reported and could not be calculated using the available data. We, therefore, have summarised these data graphically using a bubble plot with the size of the bubble proportional to the number of individuals contributing to the measure. Except for studies with more than one DAT intervention group, where more than one related measure was extracted from an article, we chose a single measure that was considered most consistent with dose-days with DAT engagement. Any extracted data that did



not fit into the measures described above were tabulated by income level, DAT type and TB type.

We found limited findings on adoption and maintenance indicators; therefore, these RE-AIM dimensions were summarised narratively. For implementation, indicators were ordered by DAT type and whether it was a technology issue or related to HCP fidelity to the intervention. Technology issues were grouped, where possible, from the person with TB or HCP perspective.

### Patient and public involvement

Patients and the public were not specifically involved in the design, conduct, reporting or dissemination plans of our research.

## RESULTS

### Characteristics of the included studies

Following deduplication, 10313 articles were identified, of which 779 satisfied the first screen and 771 were assessed for eligibility. Data extraction was attempted for 185 eligible articles, including one preprint that was not originally identified, though did fall within the database search period (online supplemental figure S1). The reference search from 68 systematic reviews yielded no articles missed in our main search. Of the 185 articles from which data extraction was attempted, 83 were excluded as no relevant data were found, leaving 102 contributing to the quantitative analysis; 87 to reach, 2 to adoption, 28 to implementation and 3 to maintenance (online supplemental figure S1). Five studies of 102 only contributed to unplanned data summaries for cellphone ownership. For a related review on the effectiveness of DATs, we searched conference abstracts from the World Conference on Lung Health from 2004 to 2023. Of these conference abstracts, we noted the quality of the implementation indicators (which are often very descriptive in full-length papers) was insufficient for inclusion, and no other search was conducted. Due to time constraints, we did attempt to identify ministry reports or technical papers. These are changes to our protocol. No unpublished reports from large-scale DAT implementation initiatives were found.

Of the 102 articles, 43, 25 and 34 were from L/LMIC, UMIC and HIC, respectively, and 89 involved treatment for TB disease (39, 25 and 25 were from L/LMIC, UMIC and HIC settings, respectively) and 13 for TB infection. The majority of articles (99/102) were from English-language journals with two from Spanish-language journals and one from a Russian-language journal. The primary DAT types reported were VST (33), digital pillbox (21), phone (20), SMS (12), 99DOTS (7), web-based app (4) and ingestion sensor (2). In addition, three articles reported on more than one DAT type, with each DAT type used by a subset of the cohort receiving TB treatment; digital pillbox and SMS, digital pillbox and 99DOTS, and VST, digital pillbox and 99DOTS.<sup>14–16</sup> Findings from VST studies mostly came from HIC settings while SMS,

pillbox and phone-based technologies were largely used in L/LMICs and UMICs. 99DOTS was predominantly used in L/LMIC settings and digital pillboxes were used in the widest range of country income settings. Of the 102 studies, 30 and 72 were published in the time periods 2000–17 and 2018–2023, respectively. In HIC settings, VST publications nearly doubled (9 in 2000–2017 and 15 in 2018–2023), in UMIC settings, pillbox publications increased 7-fold (1 in 2000–2017 (study assessed more than 1 DAT type) and 9 in 2018–2023) and in L/LMIC setting publications of phone-based interventions, including 99DOTS, increased 10-fold (2 in 2000–2017 and 20 (including a study assessing more than 1 DAT type) in 2018–2023) (see table 1 and online supplemental table S5a and S5b).

### Reach A: cellphone access among PWTB

Few studies reported on cellphone access among PWTB (38/102). We found that across a range of settings reported in 23 studies, access to cell phones varied from 50% (15/30) to 100% (574/574). Smartphone access accounted for some of the lower proportions of access in studies predominantly from HIC settings (figure 1a). Between 2% (1/54) and 31% (277/891) of PWTB were excluded from studies due to technology challenges such as the inability to regularly send SMS and lack of telephone signal or internet (nine studies). This was more common in L/LMIC than in HIC settings (figure 1b). Five studies, three of which were from UMIC, reported the percentage of PWTB not eligible for using a smart pillbox due to communication impairment or being too ill (online supplemental table S6). This proportion ranged from 2% (18/891) to 9.5% (21/221).<sup>16–20</sup> From the additional unplanned data collection, we found that shared phone access ranged from 4% (5/122) to 50% (98/197) in L/LMIC (8 studies) and 13% (19/145) to 39% (49/125) in UMIC (3 studies) (see online supplemental figure S2).

### Reach B: any DAT engagement by people with TB

Eight studies reported the proportion of people on TB disease treatment (plus one study for *M. tuberculosis* infection treatment) who agreed to use the DAT (figure 2a). The percentages ranged from 36% (110/308)<sup>21</sup> to 100% (15/15), with the vast proportion being greater than 85%; percentages were similar by DAT type. The low uptake for VST in the study by Casalme *et al*, conducted in Thailand, was hypothesised to have been due to the reluctance of PWTB and providers to try out new technologies.<sup>21</sup> Of those offered a DAT, the percentages who used the DAT at least once ranged from 33% (2746/8322) for 99DOTS to 95% (70/74) for phone-based DATs, including responses by PWTB and family members (figure 2b). Early engagement with a DAT was measured during the first 3 months of treatment (range 1–90 days). Measures ranged from 60% (in a 99DOTS intervention where a call was made on day 84)<sup>22</sup> to 89% (in a pillbox intervention where engagement over the first 90 days for *M. tuberculosis* infection

**Table 1** Summary of included reports by DAT type, RE-AIM indicators, country income level and calendar year of publication (n=102)

	HIC			UMIC			L/LMIC			Overall		
	2000–2017	2018–2023	n	2000–2017	2018–2023	n	2000–2017	2018–2023	n	2000–2017	2018–2023	n
Total number	15	19	(R; A; I)	5	(R; I; M)	5	(R; I)	20	(R; I)	10	(R; I)	33
SMS	–	1	(R)	3	(R)	3	(R; I)	2	(R)	3	(R; I)	3
Phone	1	–	(R)	–	–	–	(R; I)	5	(R)	2	(R; I)	12
99DOTS	–	–	–	–	–	–	(R)	–	(R)	–	(R; I)	7
Pillbox	4	1	(R; I)	–	(R)	–	(R; I)	9	(R; I)	3	(R)	4
VST	9	15	(R; A; I)	1	(R; I; M)	1	(R)	3	(R; I)	2	(R; I)	3
Ingestion sensor	1	1	(I)	–	(R)	–	–	–	–	–	–	–
Web-based Apps	–	1	–	–	(R, A)	–	–	1	(M)	–	(R)	2
>1 DAT intervention*	–	–	–	1	–	1	(R; I)	–	–	–	(R; I)	2
												3


n represents the number of reports.

Wei *et al*<sup>10</sup> listed under pillbox in this table. ‘99DOTS’ is a brand name for a DAT which uses medication sleeves with phone calls by the person with TB to document treatment adherence. Five studies only contributed to the unplanned data summaries for cellphone ownership. The letters, R, A, I and M, in parentheses indicate when at least one article has contributed a RE-AIM domain for grouping of articles by DAT type, calendar period and income setting. 13 studies (9 from HIC and 4 from L/LMIC) used DATs among people with TB infection of which 11 contributed data to Reach, 2 contributed to Adoption, 2 contributed to Implementation and 2 contributed to unplanned data summaries for cellphone ownership. The majority of these studies either used pillboxes (5), VST (3) or phone (3). 11 studies (3 from HIC, 5 from UMIC and 3 from L/LMIC) used DATs among people with drug-resistant TB (or included people with drug-sensitive and drug-resistant TB) of which 8 contributed data to Reach, 1 contributed data to Implementation, none contributed to Adoption and 2 contributed Maintenance. The majority of these studies either used VST (4), or phone (3) or pillboxes (2).

\*These reports looked at more than one DAT type, with each DAT type used by a subset of the cohort receiving TB treatment (digital pillbox, SMS or both<sup>16</sup>; digital pillbox or 99DOTS<sup>14</sup> and VST, digital pillbox or 99DOTS<sup>15</sup>).


A, adoption; DAT, digital adherence technology; HIC, high-income country; I, Implementation; L/LMIC, low/low-middle-income country; M, maintenance; R, reach; RE-AIM, reach, effectiveness, adoption, implementation and maintenance; SMS, short message service; TB, tuberculosis; UMIC, upper middle-income country; VST, video-supported therapy.

a proportion with cell phone access, stratified by country income level



Footnote:  
 1. \* studies where the DAT was exclusively smartphones  
 2. Daftary (2017) a small convenient sample for qualitative study from a larger trial  
 3. Guzman 1 (2023) was a 99DOTS arm in a multi-country study  
 4. Guzman 2 (2023) was an eviMed (pillbox) arm in a multi-country study


b proportion with phone/SMS issues that excluded the person with TB being offered the DAT, stratified by country income-level



Footnote:  
 Problems with phone/SMS were: being unable to SMS; problems with phone credit; problems with cellular network


**Figure 1** Measures of reach A—proportion with TB or *Mycobacterium tuberculosis* infection, eligible to use the DAT. (a) Belknap and Daftary<sup>58 59</sup> enrolled people with TB infection. (b) Johnston<sup>60</sup> enrolled people with TB infection. DAT, digital adherence technology; HIC, high-income country; L/LMIC, low/low middle-income country; SMS, short message service; TB, tuberculosis; UMIC, upper-middle-income country.

## a proportion agreeing to use the DAT, stratified by DAT type



Footnote:  
 1. includes patients currently on/completed treatment  
 2. includes patients currently on treatment  
 3. LTBI study

## b proportion of people with TB using the DAT at least once, stratified by DAT type



Footnote:  
 1. denominator of those who were sent messages  
 2. denominator of those who randomized  
 3. response from patient or family member  
 4. response from patient only  
 5. Clustering has been ignored for the 95% CI  
 6. started in first treatment month  
 7. started at any timepoint

**Figure 2** Measures of reach B—proportion of people with TB or *Mycobacterium tuberculosis* infection eligible to use the DAT, who exhibit any engagement. Casalme<sup>21</sup> enrolled people with drug-resistant TB. DAT, digital adherence technology; LTBI, latent tuberculosis infection; SMS, short message service; TB, tuberculosis; VST, video-supported therapy.

treatment was monitored<sup>23</sup>). Other varied measures of reach B are summarised in online supplemental table S7.

Four studies reported on the percentage of PWTB who stopped using the DAT during the treatment period for reasons other than death or loss to follow-up; for SMS and/or pillbox interventions the percentages ranged from 1% (12/1020) to 9.3% (9/208) (online supplemental figure S3).<sup>16 17 24 25</sup> For a VST study in the Philippines, 39.1% (43/110) stopped the DAT before they ended treatment, with 26/43 due to HCP and/or participant's decision.<sup>21</sup>

### Reach C: sustained DAT engagement by PWTB

Several studies reported engagement as a proportion of individuals who achieve a specified level of engagement with the DAT. A total of 31 observations (17 studies) were included in the meta-analysis of the proportion of DAT engagement, by binary level of engagement (online supplemental figure S4). At a threshold of 100% engagement, the summary measure for the percentage of participants exhibiting perfect engagement was 29% (95% CI 21% to 38%). The proportion of participants engaging with the DATs increased as the cut-off point reduced: at >95% cut-off, 73% (95% CI 61% to 85%) of participants showed sustained engagement with DATs; at >90% cut-off, 85% (95% CI 76% to 95%) of participants; at >85% cut-off, 85% (95% CI 77% to 94%) of participants and at >80% cut-off, 88% (95% CI 75% to 100%) of participants. In the subgroup analysis by DAT type, we found similarly that the proportion of individuals who achieved the level of engagement increased as the level decreased and that this was similar between DAT types (online supplemental figures S5-9). When assessing publication bias in the meta-analysis, restricted to studies that reported DAT engagement >90%, the LFK index was less than  $\pm 2$  (-0.77) confirmed visually on the Doi plot, suggesting that effect estimates were fairly symmetrical, providing limited evidence of publication bias (online supplemental figure S10).

Other studies reported the percentage of DAT engagement measured over total dose-days over the entire treatment course, either as the number of days with DAT engagement divided by the total days of observation ignoring the individual level or an average across individuals (figure 3, data by DAT type and income setting). The weighted average of percentage DAT engagement was 60.7% (n=6709) for 99DOTS, 80.9% (n=1201) for SMS, 81.6% (n=2179) for VST, 84.9% (n=1214) for phone and 86.6% (n=4784) for the pillbox.

Measures of DAT engagement that were varied or non-standard are summarised in online supplemental tables S9 and S10. These include data on adherence to a bedaquiline-based treatment regimen using pillboxes and a cut-off of >90% and >85%.<sup>20 26</sup>

### Adoption

We found few studies that captured adoption quantitatively. Himachal Pradesh state in northern India launched

its 99DOTS programme in 74 TB units between 2018 and 2019. The percentage of PWTB in each TB unit who were initiated on 99DOTS by HCPs was measured by a proxy, which was PWTB calling 99DOTs at least once. This varied from 0.0% to 97.5%.<sup>27</sup> This variation in 99DOTS uptake could be interpreted as a measure of HCP adoption of the technology, assessed at the health centre level. A second study conducted in South Australia reported on the roll-out of a videophone approach for direct treatment observation from 2006 (0% (0/74) of PWTB used video service) to 2010, where 52% (30/58) of PWTB used video service.<sup>28</sup>

### Implementation


For the implementation RE-AIM dimension, several findings were reported related to technology fidelity, the extent to which technology functioned as intended, and provider fidelity, the extent to which HCPs executed the intervention as designed/planned. Technological challenges were broadly categorised into those encountered by PWTB (eg, phone malfunctions, flat batteries or accessories, malfunction of Apps and software, inability to use the DAT), connectivity issues (eg, slow internet, network failure, or transmission failure) or those encountered by providers (such as poor video quality, inability to access adherence monitoring software or app) (table 2 and online supplemental table S11).

Problems with implementing SMS-based interventions were reported by five authors.<sup>29-33</sup> Issues reported by PWTB included the inability to charge the phone battery, damaged phones and no longer being able to access a shared phone. Problems with automated SMS delivery or receipt were also described. Three articles reported on technology measures with the 99DOTS intervention.<sup>14 34 35</sup>

The percentage of SMSs sent among eligible days was 90%, and the percentage of SMSs received on handsets was very high (>99%). In a large multicountry study, 59% (41/70) of HCPs had problems accessing the adherence data (on a digital platform) at some point during the study period, due to lack of electricity, poor network or the app not working, though a high percentage could access the adherence data daily (92%; 56/61). Seven studies reported implementation challenges with the pillbox.<sup>14 16 18 25 36-38</sup>

Issues included incorrect pillbox setup, lack of electricity, pillbox failure and incomplete pillbox data. Similar problems with HCPs accessing adherence were reported, as for 99DOTS. Challenges with implementing VST were reported by eight authors, the majority from HIC settings.<sup>21 39-45</sup> Technology problems experienced by PWTB primarily involved VST platform/application difficulties, including uploading of videos. The percentage of PWTB experiencing this at least once ranged from 40% to 89%, though frequent problems were rare (8%-11%). Reasons for videos not being transmitted included phone malfunction, phone loss, battery and App issues, and lack of or slow internet. System issues appear to have reduced in later calendar





**Figure 3** Percentage of engagement by digital adherence technology (DAT) type (reach C) (54 observations). HIC, high-income country; L/LMIC, low/low-middle-income country; SMS, short message service; UMIC, upper-middle-income country; VST, video-supported therapy. The plot summarises the percentage of DAT engagement over total dose days for 54 observations from 41 studies included in this analysis. Studies included SMS interventions<sup>16 24 36 60</sup>, phone<sup>61 62</sup>, 99DOTS<sup>15 27 34 63</sup>, Pillboxes<sup>10 15 16 20 25 37 64–69</sup>, VST<sup>15 39–42 70–85</sup> and Ingestion Sensors.<sup>86</sup> For Wei *et al* and Liu *et al*, pillbox openings were supplemented with pill counts so not all adherence was measured based on engagement with the DAT.<sup>10 16</sup> For de Groot *et al*, the measure of DAT engagement as pertaining to 99DOTS and Pillbox has been adapted to remove manual dosing.<sup>15</sup> Three of 41 studies (two VST and on pillbox) used DATs for PWTB infection.<sup>64 79 85</sup> Two of the 41 studies (VST and pillbox) used DATs for people with drug-resistant TB.<sup>15 20</sup> Country income level is indicated by the colour of the bubble and the size of the bubbles indicates the number of PWTB whose dose-days were included. The red line represents the average of percentage engagement, weighted by the sample size of the contributing study. The weighted means of DAT engagement by DAT type and country income level (number of persons with TB data included) are summarised in online supplemental table S8.

periods, though the number of studies was small and different VST systems were used.<sup>40 42 43</sup>

Measures of provider fidelity reflected adherence to the planned intervention by HCPs delivering the intervention (online supplemental table S12). The data extracted mainly focused on studies where the intervention included a protocolised change in management, such as a switch of PWTB to more intensive supervision and/or in-person DOT, following a display of low DAT engagement. Three studies from China that implemented a change to management reported on such issues.<sup>16 18 25</sup> The percentage of participants who started intensive management (regular visits by village/town doctor), of those eligible, ranged from 15.1% to 82.1%.<sup>16 25</sup> Despite the reported percentage being high in the latter study, this was not corroborated by participant self-report of change in the average number of visits per month, after intensified management. The percentage of participants who started DOT (daily observed treatment by a health practitioner), of those eligible, ranged from

3.8% (9/240) to 53.5% (53/99).<sup>16 18</sup> Wei *et al* reported high levels of fidelity (>88% per month), for the change to VST among those who missed >3 consecutive doses, or for whom a doctor had concerns about their adherence. Data are limited but point to better implementation of the pillbox in recent calendar years, which also coincides with a more timely review of the DAT engagement data.<sup>10</sup> Bassett *et al* reported fidelity of 72% (694 out of 976 participants) for the receipt ≥5 call attempts.<sup>32</sup>

### Maintenance

An assessment of TB patient care and support policies in high-burden countries was conducted in 2018, with responses from 23 of 30 high-TB-burden countries. Digital interventions to support treatment adherence which was incorporated into the National TB Programme policies included VST (3/23), pillboxes (2/23), 99DOTS (4/23), two-way SMS (2/23) and one-way SMS (2/23). Few countries, however, reported using these technologies, and often only in small-scale pilot studies.<sup>46</sup> A survey

**Table 2** Summary of implementation indicators by DAT type

DAT	Person	Indicator	Number of studies	Author (year)
SMS	Person with TB	Problems with phone (eg, lost, stolen, unable to charge)	1	Hermans (2017) <sup>29</sup>
		Messages not received/delivered	5	Gashu (2021), Dessie Gashu (2020), Mohammed (2016), Hermans (2017), Bassett (2016) <sup>29-33</sup>
Phone	Person with TB	Phone call failure (including due to network issues)	2	Daftary (2017), Katende (2022) <sup>59 87</sup>
99DOTS	Person with TB	SMS not received/sent	2	Kiwanuka (2022), Efo (2021) <sup>34 35</sup>
	Healthcare provider	Problems with access to adherence data due to no electricity, poor network, App not working	1	Guzman (2023) <sup>14</sup>
Pillbox	Person with TB	Incorrect use of box	1	Liu (2015) <sup>16</sup>
		Power issue	1	Liu (2015) <sup>16</sup>
		Reminders not received	1	Acosta (2022) <sup>37</sup>
		Incorrect reminders	1	de Sumari-de Boer (2016) <sup>36</sup>
	Healthcare provider	Box incorrectly setup	1	Liu (2015) <sup>16</sup>
		Problems with access to adherence data due to poor network, App not working	1	Guzman (2023) <sup>14</sup>
	General	Pillbox replaced	1	Liu (2015) <sup>16</sup>
		Missing data from pillbox	3	Liu (2023), Trajman (2010)*, Wang (2020) <sup>18 25 38</sup>
VST	Person with TB	Problems with uploading videos/app	5	Guo (2020), Chuck (2016), Nguyen (2017), Garfein (2018), Sekandi (2020) <sup>40-42 44 45</sup>
		Experiencing cellphone reception/transmission issues	3	Garfein (2018), Hoffman (2010), Sekandi (2020) <sup>41-43</sup>
		Problems due to lost phone	1	Hoffman (2010) <sup>43</sup>
	Healthcare provider	Stopped VST due to technology issues	1	Casalme† (2022) <sup>21</sup>
		Dissatisfied with video quality	1	Guo (2020) <sup>44</sup>
		Problems with video DAT	1	Bendiksen (2020) <sup>39</sup>
Ingestion sensor	General	Wearable component was not working/identified by App	1	Belknap (2013) <sup>88</sup>
Provider fidelity		Reported on components of the intervention not delivered as planned	7	Liu (2015), Wang (2020), Kiwanuka (2022), Wei† (2023), Liu (2023), Bassett (2016), Kumwihar (2022) <sup>16 18 25 32 34 78 89</sup>

\*Studies using DATs for people with TB infection.

†Enrolled people with drug-resistant TB.

‡Wei *et al*'s study was included as a preprint (2023),<sup>89</sup> though the data abstracted for this summary are from the supplement of the subsequently published article (2024).<sup>10</sup>  
DAT, digital adherence technology; SMS, short message service; TB, tuberculosis; VST, video-supported therapy.

conducted in 2015 of US states, large cities and US-affiliated Pacific Islands indicated that 42% (47/113) were using VST at that time, while 36% (41/113) had plans to do so.<sup>47</sup> A phased implementation of pillboxes for people with DS-TB adults was conducted across 3 provinces (138 counties) in China, beginning in 2017. By January 2019, all counties in those provinces were implementing pillboxes.<sup>48</sup>

## DISCUSSION

In this scoping review, we summarise quantitative findings of implementation outcomes of TB DATs using the RE-AIM framework, with most findings about dimensions of reach and implementation. Our findings provide insights into implementation challenges that might influence the effectiveness, accuracy and real-world public health impact of these technologies. Articles reporting on DATs have increased over calendar time, particularly for VST in HIC, pillboxes in UMIC and phone-based interventions in L/LMIC. Nuances of whether

DAT interventions have improved is more complex with limited data on improvements for VST and pillboxes.

Concerning reach, successful DAT engagement by PWTB requires that multiple conditions must be fulfilled, including adequate and consistent access to cellphones or DATs, eligibility to receive a DAT, early DAT engagement and sustained DAT engagement. Deconstructing reach into three groups, we found at least moderate challenges with, or high variability in, DAT or cellphone accessibility (reach A) and early (reach B) and sustained (reach C) DAT engagement. Together, challenges across these three levels of DAT accessibility or engagement likely result in a 'cascade' of problems that may sometimes considerably limit the reach of DATs across the entire population of people being treated for TB, as shown in studies that measured reach across multiple of these levels.<sup>18 49</sup> Limitations in the reach of DATs may partly explain the variable effectiveness of DATs (as engagement with DATs may be important to improve adherence behaviour) and the variable accuracy of DATs (as non-engagement

with DATs may result in non-reporting of doses taken) in different settings.<sup>6 30</sup>

Our review also quantifies factors that inhibit reach A such as lack of phone ownership, shared phone ownership, communication impairment (severe illness, hearing problems), lack of telephone signal or internet or 'phone credit'. Second, relating to early (reach B) and sustained (reach C) engagement, the evidence suggests there is a high willingness to engage with DATs initially, but the sustained engagement seems to gradually reduce. It is possible that factors such as access (eg, shared phones, unstable cellular network, internet or electricity supply), equity challenges (eg, literacy, stigma) and DAT-related issues (technology fatigue, 'ease of use') could result in a reduction in engagement with the DATs. These issues are detailed in the companion review of contextual factors for DAT implementations.<sup>8</sup> Suboptimal DAT function and cellular connectivity were common themes for facilitating conditions. Challenges with the use of digital technologies and connectivity have been raised as a concern for the equity of the implementation and use of DATs for TB treatment support, given that TB preferentially affects people of lower socioeconomic positions.<sup>51 52</sup> Evidence suggested that even though cell phone coverage (reach A) ranges from moderate to high (50%–100%), it is impacted by the ability to use a phone such as difficulty reading and sending text messages, shared ownership of phones and connectivity issues such as unreliable telephone signals or internet connection. While HIC settings recorded a slightly lower proportion with access to cell phones likely because interventions such as VST require more feature-rich mobile phones, in L/LMICs, access to cell phones may have been more affected by the connectivity issues and sharing of phones in households. On balance, we found that the proportion of people who were excluded from the use of DAT interventions was greater in LMIC than in HIC settings. We also found that individuals agreeing to use the DAT and initiating the DAT intervention (reach B) was greatest among those using VST followed by pillboxes, lesser in SMS and 99DOTS and lowest in phone-based DATs. For sustained engagement (reach C), we found a similar percentage (85%) of individuals satisfying thresholds of 80%, 85% and 90% of doses taken. For engagement over total dose-days, 99DOTs had the lowest level (60.7%) while pillbox had the highest (88.3%). We found little DAT engagement data by treatment phase. We opted not to use the summaries in de Groot *et al* as it was not possible to separate digital and manual dosing by type of DAT.<sup>15</sup> We observed high values of  $I^2$  for our meta-analysis of proportions of individuals who achieve specified levels of DAT engagement. This might have been a result of combining outcomes across different DAT types, or differences across studies in other interventions used alongside the DAT, patient demographics and health systems which may have altered DAT engagement. Cautious use of the  $I^2$  statistic for meta-analyses of proportions is recommended and high values of  $I^2$  are commonly observed.<sup>53</sup>

Compared with metrics of reach, very few studies reported quantitative measures of adoption (a measure of the interaction between technology and the HCP). However, studies that did report findings found high variability in adoption at the health centre level in the few studies reporting findings. A major reported challenge that may have affected reach or coverage was technology issues encountered by PWTB, including connectivity challenges. The inability of the DAT intervention to function as intended might have affected not only coverage but also the validation and reporting of doses and, therefore, their adherence levels reported. Therefore, it is important to anticipate and address DAT-related problems (phone malfunctions, flat batteries or accessories, crashing apps and software) by, for example, ensuring rigorous quality control and assurance in the development of devices and applications/software. An important constraint of DAT fidelity was connectivity issues, which rely on third parties such as cellular network providers to ensure a stable network. In addition, geographical obstacles may underpin challenges in connectivity on an individual level, especially in LMICs and UMICs. Concerning maintenance, even though very few studies reported on this, it seems VST, pillboxes and SMS-based interventions were the most employed. VST has been implemented mostly in Western HIC and pillboxes (with or without SMS) in Asian countries.

Implementation challenges included technology issues experienced by PWTB (problems with phone batteries, broken/lost accessories, software malfunction and DAT malfunction such as pillbox failure); connectivity issues (problems with transmission of videos due to unstable internet or lack of cell phone reception) and technology issues experienced by HCPs (inability to access adherence data and internet access). Provider fidelity mainly focused on the completeness of the components of the intervention, such as failure to initiate intensified PWTB management following low DAT engagement. Overall though we found that many studies did not report on measures of implementation or fidelity to the intervention. Most reports included were research studies and few looked at the routine roll-out of DATs, and therefore, maintenance indicators were scarce.

This study and the companion review on contextual factors are the first, to our knowledge, to systematically report on the implementation of DATs for the treatment of TB and *M. tuberculosis* infection. We found one protocol paper aiming to conduct a systematic review of barriers and facilitators of implementing pillboxes for TB treatment; results have not yet been reported.<sup>54</sup> Systematic reviews of the implementation of mHealth technologies using the RE-AIM framework, however, have been conducted in other disease areas. In an extension to a systematic review of the effectiveness of digital-supported programmes for heart disease, authors reported on RE-AIM indicators from 36 publications (27 studies).<sup>55</sup> They found few studies reported on maintenance and information on intervention fidelity. A systematic review

of studies assessing mobile phone-based interventions for diabetes self-management found limited data on adoption, implementation and maintenance.<sup>56</sup> Strengths of our study include it being a scoping review that has been conducted to a high standard, using the same methods as those used for systematic reviews, namely the systematic identification and screening, and double data extraction from studies included in the review.<sup>57</sup>

Limitations of this review include the relatively limited data available for some dimensions of the RE-AIM framework, suggesting that these are areas for which more research is needed in the future. A total of 102 articles contributed to the quantitative synthesis of DAT implementation, using the RE-AIM framework. Most data were focused on reach (87/102), followed by implementation (28/102); few studies reported data on adoption and maintenance indicators. We were not able to assess the quality of the studies as the included reports were often not aiming to measure our outcomes of interest, though these indicators were reported as additional data from their evaluations. Other limitations relate to the disparate measures used to measure DAT engagement, complicating comparability. For the meta-analysis, we have calculated the CIs using exact Clopper-Pearson intervals; this will have likely resulted in narrower CIs for some studies as clustering, such as individuals within health facilities, has been ignored. Given our interest was in measures commonly not presented as main outcomes, we decided not to include data from published conference abstracts as the data quality was anticipated to be of insufficient detail for our review, after an initial attempt. We similarly did not assess the grey literature which may have contributed some information to the maintenance dimension of the framework, data of which were lacking. We found no evidence of publication bias when restricting to similar measures (>90% engagement) suggesting that our estimates may be representative of engagement in practice. A strength of our study is that we assessed data from a range of studies implemented over a period when mobile phone use and connectivity have increased substantially globally. This study adds to the evidence base for DAT implementation, highlighting some of the nuances between countries and measures that are important to consider in planning implementation and designing new interventions.

## CONCLUSION

In conclusion, this synthesis has highlighted reach and intervention fidelity challenges to DAT implementations across varied country income settings and DAT types. These issues could inform how DAT interventions could be adapted to increase equitable access to such technologies and improve treatment outcomes.

### Author affiliations

<sup>1</sup>Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK

<sup>2</sup>Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA

<sup>3</sup>McGill International Tuberculosis Centre, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

<sup>4</sup>McGill Schulich Library of Physical Sciences, Life Sciences and Engineering, McGill University, Montreal, Quebec, Canada

<sup>5</sup>Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA

**Contributors** RS, CIC, KLF and KS conceptualised the study and designed the protocol for the scoping review. GG contributed to the design of the database search, advised on study conduct and conducted the database search. MSM, SB, CIC, CK, MZ and NF led the identification of eligible articles for the review, and RS, KLF and KS resolved conflicts during the article identification process. SB, CIC, KLF, RS and NF extracted relevant findings from articles included in the review. KLF, CIC and NF organised findings, conducted analyses and produced summaries. BP helped with organisation and reporting of findings in the supplementary appendices. CIC, NF and KLF wrote the first draft of the manuscript. All authors provided critical revisions to the initial manuscript draft and approved the final paper. KLF is the guarantor.

**Funding** This manuscript was supported by a grant from the Bill & Melinda Gates Foundation (grant INV-038215). The funding body had no role in study design, data collection, data analysis, data interpretation or manuscript writing.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

### ORCID iDs

Chimweta I Chilala <http://orcid.org/0000-0001-9039-2367>

Nicola Foster <http://orcid.org/0000-0003-4630-6243>

Genevieve Gore <http://orcid.org/0000-0003-1072-2683>

Kevin Schwartzman <http://orcid.org/0000-0002-3354-1159>

Ramnath Subbaraman <http://orcid.org/0000-0002-2063-943X>

Katherine L Fielding <http://orcid.org/0000-0002-6524-3754>

## REFERENCES

- 1 Available: <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024>
- 2 World Health Organization. What is DOTS? a guide to understanding the WHO-recommended tb control strategy known as DOTS. Switzerland World Health Organisation; 1999. Available: [https://iris.who.int/bitstream/handle/10665/65979/WHO\\_CDS\\_CPC\\_TB\\_99\\_270.pdf](https://iris.who.int/bitstream/handle/10665/65979/WHO_CDS_CPC_TB_99_270.pdf)
- 3 World Health Organisation. Consolidated guidelines on tuberculosis. module 4: treatment. Switzerland: World Health Organisation; 2022. Available: <https://www.who.int/publications/i/item/9789240048126>
- 4 World Health Organisation. Adherence to long-term therapies: evidence for action. World Health Organisation; 2003. Available:



- <https://www.paho.org/en/documents/who-adherence-long-term-therapies-evidence-action-2003>
- 5 Ridho A, Alfian SD, van Boven JFM, *et al.* Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Patients With Tuberculosis: Systematic Review of Randomized Controlled Trials. *J Med Internet Res* 2022;24:e33062.
  - 6 Mohamed MS, Zary M, Kafie C, *et al.* The impact of digital adherence technologies on health outcomes in tuberculosis: a systematic review and meta-analysis. [Preprint] 2024.
  - 7 Holtrop JS, Estabrooks PA, Gaglio B, *et al.* Understanding and applying the RE-AIM framework: Clarifications and resources. *J Clin Transl Sci* 2021;5:e126.
  - 8 Bahukudumbi S, Chilala CI, Foster N, *et al.* Contextual factors influencing implementation of tuberculosis digital adherence technologies: a scoping review guided by the re-aim framework [BMJ global health]. 2024;10:e016608.
  - 9 Tricco AC, Lillie E, Zarin W, *et al.* PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med* 2018;169:467–73.
  - 10 Wei X, Hicks JP, Zhang Z, *et al.* Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial. *The Lancet* 2024;403:913–23.
  - 11 Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. *Int J Evid Based Healthc* 2018;16:195–203.
  - 12 Shamim MA, Dwivedi P, Padhi BK. Beyond the funnel plot: The advantages of Doi plots and prediction intervals in meta-analyses. *Asian J Psychiatr* 2023;84:103550.
  - 13 Hunter JP, Saratzis A, Sutton AJ, *et al.* In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. *J Clin Epidemiol* 2014;67:897–903.
  - 14 Guzman K, Crowder R, Leddy A, *et al.* Acceptability and feasibility of digital adherence technologies for tuberculosis treatment supervision: a meta-analysis of implementation feedback. *Infectious Diseases (except HIV/AIDS)* [Preprint] 2023.
  - 15 de Groot LM, Straetemans M, Maraba N, *et al.* Time Trend Analysis of Tuberculosis Treatment While Using Digital Adherence Technologies—An Individual Patient Data Meta-Analysis of Eleven Projects across Ten High Tuberculosis-Burden Countries. *Trop Med Infect Dis* 2022;7:65.
  - 16 Liu X, Lewis JJ, Zhang H, *et al.* Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. *PLoS Med* 2015;12:e1001876.
  - 17 Wang N, Zhang H, Zhou Y, *et al.* Using electronic medication monitoring to guide differential management of tuberculosis patients at the community level in China. *BMC Infect Dis* 2019;19:844.
  - 18 Wang N, Shewade HD, Thekkur P, *et al.* Electronic medication monitor for people with tuberculosis: Implementation experience from thirty counties in China. *PLoS ONE* 2020;15:e0232337.
  - 19 Cattamanchi A, Crowder R, Kityamuwesi A, *et al.* Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. *PLoS Med* 2021;18:e1003628.
  - 20 Zelnick JR, Daftary A, Hwang C, *et al.* Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency Virus. *Clin Infect Dis* 2021;73:e1901–10.
  - 21 Casalme DJO, Marcelo DB, Dela Cuesta DM, *et al.* Feasibility and acceptability of asynchronous VOT among patients with MDR-TB. *Int J Tuberc Lung Dis* 2022;26:760–5.
  - 22 Cross A, Gupta N, Liu B, *et al.* 99DOTS: a low-cost approach to monitoring and improving medication adherence. 10th International Conference on Information and Communication Technologies and Development (ICTD); 2019
  - 23 Muyindike WR, Fatch R, Cheng DM, *et al.* Unhealthy Alcohol Use Is Associated With Suboptimal Adherence to Isoniazid Preventive Therapy in Persons With HIV in Southwestern Uganda. *J Acquir Immune Defic Syndr* 2022;91:460–8.
  - 24 Mohammed S, Siddiqi O, Ali O, *et al.* User engagement with and attitudes towards an interactive SMS reminder system for patients with tuberculosis. *J Telemed Telecare* 2012;18:404–8.
  - 25 Liu X, Thompson J, Dong H, *et al.* Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial. *Lancet Glob Health* 2023;11:e693–703.
  - 26 O'Donnell MR, Padayatchi N, Wolf A, *et al.* Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. *J Acquir Immune Defic Syndr* 2022;90:325–32.
  - 27 Chen AZ, Kumar R, Baria RK, *et al.* Impact of the 99DOTS digital adherence technology on tuberculosis treatment outcomes in North India: a pre-post study. *In Review* [Preprint] 2022.
  - 28 Wade VA, Karnon J, Elliott JA, *et al.* Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation. *PLoS One* 2012;7:e50155.
  - 29 Hermans SM, Elbireer S, Tibakabikoba H, *et al.* Text messaging to decrease tuberculosis treatment attrition in TB-HIV coinfection in Uganda. *Patient Prefer Adherence* 2017;11:1479–87.
  - 30 Dessie Gashu K, Nurhussien F, Mamuye A, *et al.* Developing and Piloting TB Medication and Refilling Reminder System in Ethiopia. *Stud Health Technol Inform* 2020;270:1251–2.
  - 31 Mohammed S, Glennerster R, Khan AJ. Impact of a Daily SMS Medication Reminder System on Tuberculosis Treatment Outcomes: A Randomized Controlled Trial. *PLoS ONE* 2016;11:e0162944.
  - 32 Bassett IV, Coleman SM, Giddy J, *et al.* Sizanani: A Randomized Trial of Health System Navigators to Improve Linkage to HIV and TB Care in South Africa. *J Acquir Immune Defic Syndr* 2016;73:154–60.
  - 33 Gashu KD, Gelaye KA, Lester R, *et al.* Effect of a phone reminder system on patient-centered tuberculosis treatment adherence among adults in Northwest Ethiopia: a randomised controlled trial. *BMJ Health Care Inform* 2021;28:e100268.
  - 34 Kiwanuka N, Kityamuwesi A, Crowder R, *et al.* Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda. *Infectious Diseases (except HIV/AIDS)* [Preprint] 2022.
  - 35 Efo E, Onjare B, Shilugu L. Acceptability, feasibility and accuracy of 99dots adherence technology in mining region of tanzania. IST-Africa Conference (IST-Africa); 2021.
  - 36 de Sumari-de Boer IM, van den Boogaard J, Ngowi KM, *et al.* Feasibility of Real Time Medication Monitoring Among HIV Infected and TB Patients in a Resource-Limited Setting. *AIDS Behav* 2016;20:1097–107.
  - 37 Acosta J, Flores P, Alarcón M, *et al.* A randomised controlled trial to evaluate a medication monitoring system for TB treatment. *Int J Tuberc Lung Dis* 2022;26:44–9.
  - 38 Trajman A, Long R, Zylberberg D, *et al.* Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. *Int J Tuberc Lung Dis* 2010;14:551–9.
  - 39 Bendiksen R, Ovesen T, Asfeldt A-M, *et al.* Use of video directly observed treatment for tuberculosis in Northern Norway. *Tidsskr Nor Laegeforen* 2020;140.
  - 40 Chuck C, Robinson E, Macaraig M, *et al.* Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. *Int J Tuberc Lung Dis* 2016;20:588–93.
  - 41 Garfein RS, Liu L, Cuevas-Mota J, *et al.* Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. *Emerg Infect Dis* 2018;24:1806–15.
  - 42 Sekandi JN, Buregyeya E, Zalwango S, *et al.* Video directly observed therapy for supporting and monitoring adherence to tuberculosis treatment in Uganda: a pilot cohort study. *ERJ Open Res* 2020;6:00175–2019.
  - 43 Hoffman JA, Cunningham JR, Suleh AJ, *et al.* Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya. *Am J Prev Med* 2010;39:78–80.
  - 44 Guo X, Yang Y, Takiff HE, *et al.* A Comprehensive App That Improves Tuberculosis Treatment Management Through Video-Observed Therapy: Usability Study. *JMIR Mhealth Uhealth* 2020;8:e17658.
  - 45 Nguyen TA, Pham MT, Nguyen TL, *et al.* Video Directly Observed Therapy to support adherence with treatment for tuberculosis in Vietnam: A prospective cohort study. *Int J Infect Dis* 2017;65:85–9.
  - 46 Cocozza AM, Linh NN, Nathavitharana RR, *et al.* An assessment of current tuberculosis patient care and support policies in high-burden countries. *Int J Tuberc Lung Dis* 2020;24:36–42.
  - 47 Macaraig M, Lobato MN, McGinnis Pilote K, *et al.* A National Survey on the Use of Electronic Directly Observed Therapy for Treatment of Tuberculosis. *J Public Health Manag Pract* 2018;24:567–70.
  - 48 Wang N, Guo L, Shewade HD, *et al.* Effect of using electronic medication monitors on tuberculosis treatment outcomes in China: a longitudinal ecological study. *Infect Dis Poverty* 2021;10:29.
  - 49 Subbaraman R, de Mondesert L, Musiimenta A, *et al.* Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities. *BMJ Glob Health* 2018;3:e001018.
  - 50 Zary M, Mohamed MS, Kafie C, *et al.* The performance of digital technologies for measuring tuberculosis medication adherence: a systematic review. *BMJ Glob Health* 2024;9:e015633.
  - 51 Saunders MJ, Wingfield T, Tovar MA, *et al.* Mobile phone interventions for tuberculosis should ensure access to mobile phones to enhance equity - a prospective, observational

- cohort study in Peruvian shantytowns. *Trop Med Int Health* 2018;23:850–9.
- 52 Boutilier JJ, Yoeli E, Rathauer J, *et al.* Can digital adherence technologies reduce inequity in tuberculosis treatment success? Evidence from a randomised controlled trial. *BMJ Glob Health* 2022;7:e010512.
  - 53 Barker TH, Migliavaca CB, Stein C, *et al.* Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. *BMC Med Res Methodol* 2021;21:189.
  - 54 Li W, Su M, Zhang W, *et al.* Barriers and facilitators of implementing electronic monitors to improve adherence and health outcomes in tuberculosis patients: protocol for a systematic review based on the Consolidated Framework for Implementation Research. *Health Res Policy Syst* 2023;21:115.
  - 55 de Moel-Mandel C, Lynch C, Issaka A, *et al.* Optimising the implementation of digital-supported interventions for the secondary prevention of heart disease: a systematic review using the RE-AIM planning and evaluation framework. *BMC Health Serv Res* 2023;23:1347.
  - 56 Yoshida Y, Patil SJ, Brownson RC, *et al.* Using the RE-AIM framework to evaluate internal and external validity of mobile phone-based interventions in diabetes self-management education and support. *J Am Med Inform Assoc* 2020;27:946–56.
  - 57 Higgins JPT, Thomas J, Chandler J, *et al.* *Cochrane handbook for systematic reviews of interventions*. Chichester, UK: John Wiley & Sons, 2023.
  - 58 Belknap R, Holland D, Feng P-J, *et al.* Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifampine Treatment of Latent Tuberculosis Infection: A Randomized Trial. *Ann Intern Med* 2017;167:689–97.
  - 59 Daftary A, Hirsch-Moverman Y, Kassie GM, *et al.* A Qualitative Evaluation of the Acceptability of an Interactive Voice Response System to Enhance Adherence to Isoniazid Preventive Therapy Among People Living with HIV in Ethiopia. *AIDS Behav* 2017;21:3057–67.
  - 60 Johnston JC, van der Kop ML, Smillie K, *et al.* The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. *Eur Respir J* 2018;51:1701488.
  - 61 Iribarren SJ, Milligan H, Chirico C, *et al.* Patient-centered mobile tuberculosis treatment support tools (TB-TSTs) to improve treatment adherence: A pilot randomized controlled trial exploring feasibility, acceptability and refinement needs. *Lancet Reg Health Am* 2022;13:100291.
  - 62 Li X, Pang X, Zhang F. Evaluation of Mobile Application for the Management of Tuberculosis Patients in Tianjin During 2019–2020. *Patient Prefer Adherence* 2022;16:321–9.
  - 63 Thakkar D, Piparva KG, Lakkad SG. A pilot project: 99DOTS information communication technology-based approach for tuberculosis treatment in Rajkot district. *Lung India* 2019;36:108–11.
  - 64 Aillinger RL, Black PL, Lima-Garcia N. Use of electronic monitoring in clinical nursing research. *Clin Nurs Res* 2008;17:89–97.
  - 65 Guo G, Sun L, Wushoue Q, *et al.* eDOTS: a new system applied for improving the treatment of pulmonary tuberculosis patients from Kashgar villages and Urumqi streets in Xinjiang, China. *In Review [Preprint]* 2021.
  - 66 Manyazewal T, Woldeamanuel Y, Holland DP, *et al.* Effectiveness of a digital medication event reminder and monitor device for patients with tuberculosis (SELFTB): a multicenter randomized controlled trial. *BMC Med* 2022;20:310.
  - 67 Park S, Sentissi I, Gil SJ, *et al.* Medication Event Monitoring System for Infectious Tuberculosis Treatment in Morocco: A Retrospective Cohort Study. *Int J Environ Res Public Health* 2019;16:412.
  - 68 van den Boogaard J, Lyimo RA, Boeree MJ, *et al.* Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. *Bull World Health Organ* 2011;89:632–9.
  - 69 Velen K, Nguyen T-A, Pham CD, *et al.* The effect of medication event reminder monitoring on treatment adherence of TB patients. *Int J Tuberc Lung Dis* 2023;27:322–8.
  - 70 Krueger K, Ruby D, Cooley P, *et al.* Videophone utilization as an alternative to directly observed therapy for tuberculosis. *Int J Tuberc Lung Dis* 2010;14:779–81.
  - 71 Story A, Aldridge RW, Smith CM, *et al.* Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. *Lancet* 2019;393:1216–24.
  - 72 Bachina P, Lippincott CK, Perry A, *et al.* Programmatic Adoption and Implementation of Video-Observed Therapy in Minnesota: Prospective Observational Cohort Study. *JMIR Form Res* 2022;6:e38247.
  - 73 DeMaio J, Schwartz L, Cooley P, *et al.* The application of telemedicine technology to a directly observed therapy program for tuberculosis: a pilot project. *Clin Infect Dis* 2001;33:2082–4.
  - 74 Garfein RS, Liu L, Cuevas-Mota J, *et al.* Evaluation of recorded video-observed therapy for anti-tuberculosis treatment. *Int J Tuberc Lung Dis* 2020;24:520–5.
  - 75 Garfein RS, Collins K, Muñoz F, *et al.* Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study. *Int J Tuberc Lung Dis* 2015;19:1057–64.
  - 76 Holzman SB, Atre S, Sahasrabudhe T, *et al.* Use of Smartphone-Based Video Directly Observed Therapy (vDOT) in Tuberculosis Care: Single-Arm, Prospective Feasibility Study. *JMIR Form Res* 2019;3:e13411.
  - 77 Holzman SB, Zenilman A, Shah M. Advancing Patient-Centered Care in Tuberculosis Management: A Mixed-Methods Appraisal of Video Directly Observed Therapy. *Open Forum Infect Dis* 2018;5:ofy046.
  - 78 Kumwiche P, Chongsuvivatwong V, Prapree T. Video-Observed Therapy With a Notification System for Improving the Monitoring of Tuberculosis Treatment in Thailand: Usability Study. *JMIR Form Res* 2022;6:e35994.
  - 79 Lam CK, McGinnis Pilote K, Haque A, *et al.* Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifampine: An Implementation Study. *J Med Internet Res* 2018;20:e287.
  - 80 Lippincott CK, Perry A, Munk E, *et al.* Tuberculosis treatment adherence in the era of COVID-19. *BMC Infect Dis* 2022;22:800.
  - 81 Mirsaeidi M, Farshidpour M, Banks-Tripp D, *et al.* Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective. *Eur Respir J* 2015;46:871–4.
  - 82 Olano-Soler H, Thomas D, Joglar O, *et al.* Notes from the Field: Use of Asynchronous Video Directly Observed Therapy for Treatment of Tuberculosis and Latent Tuberculosis Infection in a Long-Term-Care Facility - Puerto Rico, 2016–2017. *MMWR Morb Mortal Wkly Rep* 2017;66:1386–7.
  - 83 Perry A, Chitnis A, Chin A, *et al.* Real-world implementation of video-observed therapy in an urban TB program in the United States. *Int J Tuberc Lung Dis* 2021;25:655–61.
  - 84 Rajalahti I, Kreivi H-R, Ollgren J, *et al.* Asynchronous video supported treatment of tuberculosis is well adopted in a real-world setting - an observational study comparing two distinct applications. *Infect Dis (Lond)* 2023;55:303–6.
  - 85 Zhao A, Butala N, Luc CM, *et al.* Telehealth Reduces Missed Appointments in Pediatric Patients with Tuberculosis Infection. *TropicalMed* 2022;7:26.
  - 86 Browne SH, Umlauf A, Tucker AJ, *et al.* Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. *PLoS Med* 2019;16:e1002891.
  - 87 Katende KK, Amiyo MR, Nabukeera S, *et al.* Design, development, and testing of a voice-text mobile health application to support Tuberculosis medication adherence in Uganda. *PLoS ONE* 2022;17:e0274112.
  - 88 Belknap R, Weis S, Brookens A, *et al.* Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. *PLoS ONE* 2013;8:e53373.
  - 89 Wei X, Hicks JP, Zhang Z, *et al.* Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial. *SSRN [Preprint]* 2023.